How i treat cryptococcosis in organ transplant recipients

Transplantation

Volumn 93, Issue 1, 2012, Pages 17-21

  Singh, Nina ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cryptococcus; Fungal infection; Transplant

Indexed keywords

ALBACONAZOLE; ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CRYPTOCOCCAL ANTIGEN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VORICONAZOLE;

ADJUVANT THERAPY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTHRITIS; AUTOIMMUNE DISEASE; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCEMIA; CRYPTOCOCCOSIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FUNGUS TRANSMISSION; GRAFT REJECTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INCIDENTAL FINDING; INFECTION PREVENTION; INFLAMMATORY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG NODULE; LUNG TRANSPLANTATION; MENINGOENCEPHALITIS; MINIMUM INHIBITORY CONCENTRATION; MYOCARDITIS; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PERITONITIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY CRYPTOCOCCOSIS; RELAPSE; RETRANSPLANTATION; REVIEW;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CALCINEURIN; CRYPTOCOCCOSIS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PREVALENCE; RISK FACTORS; TRANSPLANTATION;

EID: 84655166515     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318236cd1a     Document Type: Review

References (66)

1. Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23: 525.
2. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007; 9: 22.
3. Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: Evidence-based evolving trends. Clin Infect Dis 2009; 48: 1566.
4. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 375.
5. Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009; 49: 1721.
6. Singh N, Husain S, De Vera M, et al. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore). 2004; 83: 188.
7. Chuang YM, Ho YC, Chang HT, et al. Disseminated cryptococcosis in HIV-uninfected patients. Eur J Clin Microbiol Infect Dis 2008; 27: 307.
8. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33: 690.
9. Jean SS, Fang CT, Shau WY, et al. Cryptococcaemia: Clinical features and prognostic factors. QJM 2002; 95: 511.
10. Kinjo K, Satake S, Ohama T. Cryptococcal pleuritis developing in a patient on regular hemodialysis. Clin Nephrol 2009; 72: 229.
11. Eriguchi M, Nagao T, Kamimura T, et al. Pulmonary capillary embolism caused by cryptococcemia in a hemodialysis patient. Clin Nephrol 2009; 71: 88.
12. Yinnon AM, Solages A, Treanor JJ. Cryptococcal peritonitis: Report of a case developing during continuous ambulatory peritoneal dialysis and review of the literature. Clin Infect Dis 1993; 17: 736.
13. Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51: 1062.
14. Iitaka K, McEnery PT, West CD. Successful renal transplantation after generalized cryptococcosis. J Pediatr 1978; 92: 422.
15. Mills SA, Seigler HF, Wolfe WG. The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg 1975; 182: 617.
16. Swenson RS, Kountz SL, Blank N, et al. Successful renal allograft in a patient with pulmonary cryptococcus. Arch Intern Med 1969; 124: 502.
17. Sifri CD, Sun HY, Cacciarelli TV, et al. Pretransplant cryptococcosis and outcome after liver transplantation. Liver Transpl 2010; 16: 499.
18. Concejero AM, Yong CC, Chen CL, et al. Solitary pulmonary nodule in the liver transplant candidate: Importance of diagnosis and treatment. Liver Transpl 2010; 16: 760.
19. Görlach J, Fox DS, Cutler NS, et al. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000; 19: 3618.
20. Ooi HS, Chen BT, Lim CH, et al. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971; 11: 428.
21. Baddley JW, Schain DC, Gupte AA, et al. Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis 2011; 52: e94.
22. Lyon M, Kaul D, Ehsan A, et al. Infectious disease transmission from organ donors with meningitis or encephalitis [abstract 572]. Presented at the American Transplant Congress, vol 11(s2), Philadelphia PA. Am J Transplant 2011.
23. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: Report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75: 142.
24. Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992; 24: 1898.
25. Singh N, Alexander BD, Lortholary O, et al. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46: e12.
26. Snow RM, Dismukes WE. Cryptococcal meningitis: Diagnostic value of cryptococcal antigen in cerebrospinal fluid. Arch Intern Med 1975; 135: 1155.
27. Lortholary O, Nunez H, BraunerMW,et al. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2004; 25: 145.
28. Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: An overview. Am J Transplant 2002; 2: 575.
29. Aberg JA, Mundy LM, Powderly WG. Pulmonary crytococcosis in patients without HIV infection. Chest 1999; 115: 734.
30. Singh N, Forrest G; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S192.
31. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291.
32. Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992; 36: 977.
33. Wilson E, Thorson L, Speert DP. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991; 35: 796.
34. Stein SH, Little JR, Little KD. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell Immunol 1987; 105: 99.
35. Wolf JE, Stein SH, Little KD, et al. Amphotericin B selectively stimulates macrophages from high responder mouse strains. Immunopharmacol Immunotoxicol 1991; 13: 221.
36. Balloy V, Huerre M, Latg é JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494.
37. Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines inhumanmonocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397.
38. Arning M, Kliche KO, Heer-Sonderhoff AH, et al. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459.
39. Eierman DF, Yagami M, Erme SM, et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci U S A 1995; 92: 2815.
40. Devine DV, Wong K, Serrano K, et al. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta 1994; 1191: 43.
41. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: Immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47: 226.
42. Kontoyiannis DP, Lewis RE, Alexander BD, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008; 52: 735.
43. Sanglard D, Ischer F, Monod M, et al. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agentsandother metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300.
44. Egner R, Rosenthal FE, Kralli A, et al. Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. Mol Biol Cell 1998; 2: 523.
45. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for lesscommon, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122.
46. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 291.
47. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 1580.
48. Guinea J, Hagen F, Pelaez T, et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 2010; 48: 942.
49. Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 2005; 40: 1756.
50. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395.
51. Sun HY, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis 2009; 22: 394.
52. Malek SK, Obmann MA, Gotoff RA, et al. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81: 17.
53. Sun HY, Forrest G, Alexander BD, et al. Predictors of immune reconstitution syndrome (IRS) in transplant recipients with cryptocococcosis [abstract #M-1138]. Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago IL, September 17-20, 2011.
54. Lanternier F, Chandesris MO, Poirée S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7: 2826.
55. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome; case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516.
56. Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5: e11416.
57. Zhang TY, Daynes RA. Glucocorticoid conditioning of myeloid progenitors enhances TLR4 signaling via negative regulation of the phosphatidylinositol 3-kinase-Akt pathway. J Immunol 2007; 178: 2517.
58. Broady R, Levings MK. Graft-versus-host disease: Suppression by statins. Nat Med 2008; 14: 1155.
59. Chow SC. Immunomodulation by statins: Mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2009; 57: 243.
60. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008; 111: 3901.
61. Arend SM, Leyten EM, Franken WP, et al. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007; 45: 1470.
62. Pech T, Finger T, Fujishiro J, et al. Perioperative infliximab application ameliorates acute rejection associated inflammation after intestinal transplantation. Am J Transplant 2010; 10: 2431.
63. Gerlach UA, Koch M, Müller HP, et al. Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation. Am J Transplant 2011; 11: 1041.
64. Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with C. neoformans infection. Transplantation 2005; 80: 1033.
65. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferongamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189: 2185.
66. Armstrong-James D, Teo IA, Shrivastava S, et al. Exogenous interferongamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant 2010; 10: 1796.